FAQ on ARTBIO's Expansion of Board of Directors and Transition of Co-Founder

What is the significance of ARTBIO’s new board appointments?

The new appointments bring world-class experience and insights to ARTBIO, supporting the company’s commitment to advancing its alpha radioligand therapy programs and strategic growth following its Series B funding round.

Who are the new members appointed to ARTBIO’s Board of Directors?

The new members are Maha Katabi, Ph.D., CFA; Robert Mittendorff, M.D., MBA; Julie O’Neill, MBA; and Gabe Gelman, each bringing extensive experience in biotech, healthcare, and finance to guide ARTBIO’s strategic initiatives.

Why is Dr. Roy Larsen transitioning to the Technical Advisory Board?

Dr. Larsen, a co-founder and pioneer in radiopharmaceuticals, is transitioning to contribute his expertise in a more focused capacity within the newly created Technical Advisory Board, ensuring his continued impact on ARTBIO’s innovations.

What expertise do the new board members bring to ARTBIO?

The new members offer diverse expertise including biotech investment, healthcare strategy, pharmaceutical operations, and financial advisory, which will be instrumental in ARTBIO’s program expansion and growth strategies.

How will these changes benefit ARTBIO’s mission?

These changes are expected to accelerate the advancement of ARTBIO’s alpha radioligand therapies by leveraging the new board members’ strategic insights and Dr. Larsen’s technical expertise, aiming to bring novel cancer therapies to market.

What is ARTBIO’s focus in the radiopharmaceutical field?

ARTBIO is focused on developing a new class of 212Pb alpha radioligand therapies (ARTs) designed to have the highest patient impact in treating cancer.

Where can I find more information about ARTBIO?

More information about ARTBIO can be found on their official website at https://artbio.com/.